Small medical device companies are bypassing expensive sales tactics by offering big discounts on orthopedic devices to remain competitive in the market, according to a Wall Street Journal report.
Spinal Tech
RSB Spine, a Cleveland-based spine device company, reported a 131 percent sales increase for the second quarter of 2011 over the same time period in 2010, according to a company news release.
Medtronic has launched the CD Horizon Fenestrated Screw Spinal System in Europe and has plans to introduce it in India, Singapore and Australia in the coming months, according to the company news release.
RTI Biologics, an Alachua, Fla.-based orthopedic device company, has launched the BioAdapt DBM Foam, a flexible demineralized bone matrix solution, according to a company news release.
Medtronic has commercially released the Kyphon Xpander II Inflatable Bone Tamp and Kyphon Inflation Syringe as part of the Kyphon Xpander II IBT System for treating vertebral compression fractures, according to a company news release.
Advertisement
Dr. David J. Berkoff, MD, a professor at Duke University and team physician for the school's student athletes, was recently named to the board of directors of Fuse Science, an Aventura, Fla.-based company, according to a company news release.
Raleigh, N.C.-based Pioneer Surgical Technology has launched the nanOss Bioactive Loaded, a pre-filled mixing syringe for use during minimally invasive orthopedic and spine procedures, according to a company news release.
Cayenne Medical, a Scottsdale, Ariz.-based sports medicine device company, launched the CrossFix II Meniscal Repair System, the second generation of a device designed to treat traumatic meniscal tears, according to a company news release.
Aesculap Implant Systems, a B. Braun company, has launched the Hydrolif Vertebral Body Replacement system indicated for treating burst fractures and tumor removal of the thoracolumbar spine, according to a company news release.
Omar Ishrak, chairman and CEO of Medtronic, responded to a series of articles attacking the company's original trials and promotion of recombinant human bone morphogenic protein-2, saying that integrity and patient safety are his highest priorities, according to a company…